Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Defense Play in Motion - WTC Reaction -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (61)	9/20/2001 3:34:48 PM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 225

I would add GNLB Naz 2.00 (as high today as 2.70) to the biodefense group...there are not many: In the war against bacterial resistance to antibiotics, Genelabs Technologies targets disease at the source, developing small-molecule drugs that bind to DNA and change the activity of disease-causing genes. Its MERLIN technology identifies molecules' DNA-binding preferences and, ultimately, which sequences will host DNA-binding drugs. Applications include cancer therapies and treatments for bacterial and viral infections. The company is awaiting FDA approval for Aslera, a new therapy for lupus. Genelabs also researches genetic technologies for use against biological warfare agents. Subsidiary Genelabs Diagnostics makes diagnostic test kits, reagents, and equipment